Siponimod - Novartis

Drug Profile

Siponimod - Novartis

Alternative Names: BAF-312

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Novartis
  • Class Anti-inflammatories; Azetidines; Carboxylic acids; Immunotherapies; Neuroprotectants; Skin disorder therapies; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Dermatomyositis; Polymyositis; Stroke
  • No development reported Liver failure; Renal failure

Most Recent Events

  • 22 Mar 2018 Novartis intends to make regulatory submissions for siponimod for secondary progressive Multiple sclerosis in US in early 2018
  • 22 Mar 2018 Updated efficacy data from the phase III EXPAND study in Multiple sclerosis released by Novartis
  • 24 Dec 2017 Phase-II clinical trials in Stroke (due to intracerebral haemorrhage) in USA (IV) (NCT03338998)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top